Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy, Lung Cancer, June 2006, Elsevier,
DOI: 10.1016/j.lungcan.2006.03.004.
You can read the full text:

Read

Contributors

The following have contributed to this page